BDNF and myeloid sarcoma: This finding was further supported by the Quade nonparametric analysis of covariance, adjusted for baseline values, which indicated that omega‐3 fatty acid supplementation had no significant effect on BDNF or hs‐CRP levels in patients with MS (p = 0.644 and p = 0.533, respectively).